The following is a summary of “Karyotype evolution of myelodysplastic syndrome and acute myeloid leukemia with TP53 mutations,” published in the February 2025 issue of the International Journal of ...

Myelodysplasia (MDS) and acute myeloid leukemia (AML) are heterogeneous, closely associated diseases arising de novo or following chemotherapy with alkylating agents, topoisomerase II inhibitors ...

Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies,” published in the February 2025 issue of American Journal of Hematology by Senapati et ...

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “A case report of donor cell–derived ...

Mikkael A. Sekeres, MD, Sylvester Comprehensive Cancer Center, discusses the potential benefits of treosulfan, a newly ...

Saeed Sadeghi, MD, discusses treatment options in low-risk myelodysplastic syndrome at a Case-Based Roundtable event.

Treatment with tuspetinib in combination with Venclexta and Vidaza in newly diagnosed acute myeloid leukemia showed safety ...

The FDA has approved GRAFAPEX™ and fludarabine as a preparative regimen in acute myeloid leukemia or myelodysplastic syndrome prior to alloHSCT. The Food and Drug Administration (FDA) has approved ...

The team identified a specific population of immune cells that play a critical role in successful treatment of relapsed acute myeloid leukemia (AML). A research team from Columbia Engineering and ...

with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in patients ages 1 year and older with acute myeloid leukemia (AML) or myelodysplastic syndrome ...

Orca Bio announces it met the primary endpoint in its pivotal Phase 3 clinical study for its lead allogeneic T-cell immunotherapy, Orca-T.